Haleon cuts 2026 revenue growth forecast on weak flu season and China disruption
Haleon lowered its full-year organic revenue growth forecast to about 2.5% on weak cold-medicine demand and a China regulatory setback, Reuters reported.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Haleon, the British consumer health company, lowered its full-year organic revenue growth forecast to around 2.5%, from a previous 3% to 5%, according to Reuters. Weak cold and flu demand in North America, its largest market, held back orders, and a regulatory setback in China hurt sales. Organic revenue rose 2.6% in the quarter ended September 30, short of the 3.2% analysts expected. Oral Health was a bright spot, with sales up 8.8%.
why it matters
Haleon is a large consumer health name, so a weaker revenue outlook can weigh on its shares and on the wider sector. The company also expects a hit of £15 million to £20 million to fourth-quarter revenue from its Brazil go-to-market changes, which investors will watch in upcoming updates.
market impact
Haleon shares: a weaker revenue outlook pressures the company's stock
- Haleon shares pressure down — lower forecast, weak cold-medicine demand and China shipment suspension
tags
instruments
sources
- Sensodyne maker Haleon cuts revenue growth forecast on weak flu season, China disruption — Reuters, 29 October 2026 at 07:37 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗